

Presentation and Chair's address to the 2026 Annual General Meeting

28 October 2026

Melbourne, Australia, 28 October 2026: 4DMedical Limited (ASX: 4DX, "4DMedical" or the "Company") attaches the following materials to be presented at the Annual General Meeting of Shareholders to be held today at 10:00am (AEDT):

1. Script of the prepared address to be given by the Chair; and
2. Presentation slides to accompany the meeting.

—ENDS—

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Investor Relations

investor.relations@4dmedical.com

Administration

Company Secretary

companysecretary@4dmedical.com

Media Enquiries

Julia Maguire

julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionizing respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology**® transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS®)**, **CT LVAS™**, and the ground-breaking **CT:VQ®** solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalised patient care. With advanced AI capabilities added through its acquisitions of Imbio in 2023 and contextflow in 2026, 4DMedical is redefining how respiratory disease is imaged, understood and treated worldwide.

Learn more at www.4dmedical.com

Melbourne

Level 7 Melbourne Connect
700 Swanston Street
Carlton VIC 3053
Tel: +61 (3) 9545 5940

Los Angeles

21255 Burbank Boulevard
Suite 120
Woodland Hills CA 91367
Tel: +1 (818) 403-8490

4DMedical Limited
ABN: 31 161 684 831
Email: info@4DMedical.com
www.4DMedical.com

Dear Shareholders,

Welcome to 4DMedical's 2026 AGM. I am pleased to present our Annual Report for financial year 2026 and reflect on a year that has been both significant and transformational for our Company. Over the past twelve months, we have continued to strengthen our position as a growing leader in respiratory imaging and diagnostics.

On behalf of the 4DMedical Board I extend my thanks to our shareholders. We are grateful for your support including participation in capital raises and delighted to welcome new shareholders at this exciting point in our clinical and commercial growth.

I will start by sharing three highlights:

Firstly, the continued success of CT:VQ®.

Achieving FDA Clearance and CMS reimbursement for our breakthrough product CT:VQ® in early FY26 was a pivotal milestone. These approvals set the pace for adoption of CT:VQ® by leading US Academic Research Centres and other imaging facilities which will be drivers for increasing commercial momentum.

Secondly, FY26 marked an important expansion of our international footprint.

Through the acquisition of contextflow, we established a meaningful presence in Europe - opening access to new markets and strengthening our product offering.

Wider regulatory clearances achieved across Europe, UK, Canada and Australia opens significant opportunities for 4DMedical across the global healthcare system.

Thirdly, our continued focus on strategic partnerships to accelerate uptake and awareness of our product suite.

We expanded our five-year distribution agreement to include CT:VQ with Philips, who act as the exclusive partner to U.S. government customers – including Department of Veterans' Affairs and Department of Defence. Together, we are enhancing access to our technologies through an established and highly trusted commercial channel.

Underlying these achievements is strong operational execution.

Operating revenue in FY26 was \$7.1 million, up 21% vs FY25, with gross margins exceeding 90%.

Operating expenditure (excluding non-cash share-based payments) for FY26 was \$45.7 million, broadly in line with FY25 (\$45.5 million), reflecting disciplined cost management while continuing to invest in growth initiatives.

4DMedical's operational performance during FY2026 evidences our ability to translate promise into clinical outcomes.

- We delivered 344,075 pulmonary & cardiovascular scans – an increase in 77% over FY25.
- These scans were delivered across 540 sites globally - an increase of 39% on last financial year.

This level of utilisation reflects the increasing confidence that clinicians place in our products, and the expanding role our technology is playing in patient care around the world.

The Company is well positioned for our next phase of growth, and I have decided this AGM is the right time to step down and hand over. I thank my fellow Directors for their stewardship and support. It has been my privilege to serve on the 4DMedical Board and chair the Company through many transformational achievements; seeing 4DMedical go from IPO, bring to market outstanding and innovative products, achieve regulatory approvals, and build the foundations and key customer base for commercial success.

I wish to acknowledge the refreshed leadership appointments in place at the close of this AGM:

- Julian Sutton – current CFO and Executive director - as incoming Chair;
- Professor Christine Jenkins AM – as independent Non-Executive Director;
- Chris Cox – current Financial Controller and former interim CFO – promoted to CFO; and
- Beth Plunkett – current Head of Legal – promoted to General Counsel.

Closing Remarks

I am very proud of our extraordinary global team and their commitment to 4DMedical's mission to improve global health outcomes. I have every confidence that the team has the capability to advance its mission and commercial growth.


I will continue to closely watch 4DMedical's progress, now, like you, as a supporter and shareholder.

On behalf of the Board of 4DMedical, thank you for your attendance today and I kindly seek your approval of the resolutions placed before you.



4D Medical Limited (ASX:4DX)
Annual General Meeting
28 October 2026

Delivering Next- Generation Cardiopulmonary Imaging to the World



Copyright © 4D Medical Limited 2026
Level 7, Melbourne Connect
700 Swanston Street
Melbourne, Victoria 3053
Australia
ABN 31 161 684 831
www.4dmedical.com

Disclaimer



This presentation has been prepared by 4DMedical Limited (ACN 161 684 831) (Company or 4DMedical). This presentation contains summary information about the Company, its subsidiaries and their activities current as of 28 October 2026 unless otherwise stated and the information remains subject to change without notice. This information is general in nature, does not purport to be complete and is subject to change without notice.

Not an offer or financial product advice

The Company is not licensed to provide financial product advice. This presentation is for information purposes only and does not constitute financial product or investment advice or a recommendation to acquire, hold or dispose of securities in 4DMedical. It has been prepared without taking into account the objectives, financial situation or needs of any particular person.

This presentation is not a prospectus, product disclosure statement, pathfinder document for the purposes of section 734(9) of the Australian *Corporations Act 2001* (Cth) (Corporations Act) or other offer document under Australian law or the law of any other jurisdiction. Neither this presentation nor anything contained in it shall form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in, or refrain from engaging in, any transaction. Nothing in this presentation constitutes legal, financial, tax or other advice. Recipients of the presentation should conduct their own investigation, evaluation and analysis of the business and other data and information set out in the presentation.

Forward-looking statements

This presentation may contain forward-looking statements based on current expectations and assumptions. Actual results may differ materially due to risks and uncertainties, many of which are beyond the Company's control. Except as required by law, the Company undertakes no obligation to update these statements.

The distribution of this presentation in jurisdictions outside Australia may be restricted by law and you should observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

Agenda



1. Opening & introductions
2. Chair's address
3. CEO's address
4. Procedural matters
5. Formal business & poll
6. Q&A & close of meeting

Board of Directors – significant medical and commercial sector experience



Lil Bianchi

Non-Executive Chair (*Outgoing*) &
Chair of the Audit and Risk Committee
Experienced contributor of business transformations for US
listed technology companies with a beneficial technology
product expertise in AI and SaaS offerings.



Julian Sutton

Executive Director & CFO (*Incoming Chair*)
Experienced executive with specialisation in commercialisation,
capital markets and strategic growth for innovative healthcare
technology companies. Funds management experience via
Schroders and Credit Suisse in London.



Dr Andreas Fouras PhD

Managing Director and CEO
Award-winning aerospace engineer and innovator
responsible for the conception and development of
4DMedical's core technologies.



John Livingston

Non-Executive Director & Chair of the
Remuneration and Nomination Committee

Founding partner of ASX-listed
Integral Diagnostics (ASX:IDT) and
an industry leader in the
implementation of PACS and RIS in
radiological settings.



Dr Geraldine McGinty MD

Non-Executive Director

Internationally recognised expert in health care
strategy and imaging economics, and prominent
advocate for patient-centred care. Professor of
Radiology and Population Health Sciences at Weill
Cornell Medicine in New York City.



Dr Robert A. Figlin MD

Non-Executive Director & Chair of the
Medical Advisory Committee

Globally recognised leader in genitourinary
and thoracic oncology, as well as Editor of
the Kidney Cancer Journal and Spielberg
Family Chair in Hematology/Oncology at
Cedars Sinai.



Prof Christine Jenkins AM

Non-Executive Director


Leading Australian respiratory physician and
pioneering researcher transforming care for
people with asthma and chronic lung
diseases through groundbreaking research,
innovation and clinical leadership.

Chair's address



Lil Bianchi

Non-Executive Chair (*Outgoing*)




CEO's address



Dr Andreas Fouras PhD

Managing Director & CEO



4DMedical: An overview



4DMedical is a global medical technology company, changing the outcome for patients with lung disease by revolutionising respiratory imaging through ventilation and perfusion analysis

The leading pulmonary & cardiothoracic imaging analysis company in the market

4DMedical was founded in Melbourne in 2013 to bring breakthrough lung functional imaging technologies to patient care.

- ✓ CT:VQ® - the world's first and only non-contrast lung ventilation and perfusion product
- ✓ Listed on the ASX in 2020
- ✓ Joined the ASX200 in 2026
- ✓ 100+ patented technologies
- ✓ 9 FDA-cleared SaaS products
- ✓ Deep clinical, commercial and technical expertise
- ✓ Global brands supporting distribution
- ✓ 181 global team members across the Australia, the U.S. and Europe

FY26: Foundations for rapid growth

Regulatory access, clinical evidence, reimbursement and geographic footprint in place.

**6 CT:VQ[®]
markets**

regulatory cleared

**↑ 39 %
SaaS sites**

540 global sites

**↑ 77 %
scans**

344k across FY26

**↑ 21 %
revenue**

FY26 \$7.1m

\$278m

Cash at 30 June 2026



Regulatory & reimbursement

- U.S. FDA clearance of CT:VQ[®] (Sep 2025)
- CMS reimbursement at US\$650.50 per scan
- Authorised in EU, UK, Canada, NZ and Australia; paid AU contracts within days of TGA listing



U.S. commercial adoption

- 5 leading AMCs on full commercial terms, incl. Cleveland Clinic, Stanford and UChicago
- SimonMed: 170-site outpatient network, no evaluation phase
- Philips North America distribution with CT:VQ[®] minimum order commitment



Clinical evidence & market expansion

- AJRCCM: LVRS responder outcome rate improved from 46% to 76%
- CLEAR PE program at Mass. General supports U.S. obtainable market to US\$3b
- AstraZeneca (Brazil) and GSK pharma contracts




Global platform & capital

- EU presence established, contextflow acquisition; 25,000-procedure German screening contract
- Lung eco-system partnerships | RevealDx investment, Azra AI partnership
- \$233m raised across two placements; S&P/ASX 200 inclusion

Share price performance since 1 July 2025




Strong share price performance, including relative to ASX listed med-tech industry peers



4DMedical's product portfolio: a complete lung health solution



A market-leading portfolio of pulmonary structure, function and cardiovascular imaging products delivered via a powerful, scalable SaaS platform

Category	Product	 FDA	 CMS reimbursement	 CE Mark	 TGA	 CMDR	 MHRA	 Medsafe	 ANVISA
 Pulmonary Function	CT:VQ® (CT-based non-contrast ventilation & perfusion imaging)	✓	✓	✓	✓	✓	✓	✓	
	CT LVAS™ (CT-based non-contrast ventilation analysis)	✓	✓	✓	✓	✓		✓	
	XV LVAS® (Dynamic ventilation analysis – fluoroscopy)	✓	✓	✓	✓			✓	
	LDAf™ (Lung Density Analysis – Functional) (Air trapping, emphysema)	✓	✓	✓	✓	✓	✓		✓
 Pulmonary Structure	ADVANCE Chest CT™ (Lung cancer screening)			✓			✓		
	LDAi™ (Lung Density Analysis – Inspiration) (Emphysema, HAA, Fissures)	✓		✓	✓	✓	✓		✓
	LTA™ (Lung Texture Analysis) (Interstitial lung diseases (ILD) screening, Fibrosis)			✓	✓	✓	✓		✓
	IQ-UIP™ (Idiopathic pulmonary fibrosis (IPF) screening)	✓	✓			Submitted			
 Cardiovascular	CAC™ (Coronary Calcification, Heart Disease)	✓	✓	✓	Submitted	✓			✓
	PHA™ RV/LV (Hypertension (RV/LV, MPA, Pa/Ao))	✓		✓	✓				✓

CT:VQ[®] FDA clearance, CMS reimbursement



Transformational milestone: CT:VQ[®] FDA clearance



- ✓ CT:VQ[®] becomes the world's first and only non-contrast, CT-based ventilation-perfusion imaging technology to receive FDA clearance
- ✓ Reimbursement for CT:VQ[®] from the U.S. Centers for Medicare and Medicaid Services (CMS) at US\$650.50 per scan
- ✓ Introduction of CT:VQ[®] into the U.S. market will drive long-term growth in demand for ventilation-perfusion scans beyond the traditional nuclear VQ indications

Compelling clinical validation package across multiple lung conditions

- ✓ 4DMedical conducted extensive clinical testing to prove that CT:VQ[®] produces the same diagnostic results as SPECT Nuclear VQ imaging, while offering significant practical advantages such as eliminating logistical challenges, radiation exposure, and the infrastructure and specialist personnel requirements of nuclear imaging

Significant, scalable commercial opportunity

- ✓ Large addressable market:
 - 1 million+ VQ scans performed annually in the U.S.
 - US\$1.1 billion U.S. market
 - US\$2.6 billion global market
 - Instantly compatible with ~14,500 CT scanners in the U.S.



CT:VQ® early adopters




Strategy for adoption at top-tier, influential, U.S. academic medical centres and health systems

Top 20 U.S. Hospitals
Interventional Pulmonology ¹



Top 20 – U.S. Hospitals *



AMCs signed commercial CT:VQ® contracts within months of FDA clearance:

- Stanford University
- Cleveland Clinic
- University of Miami
- University of Chicago
- UC San Diego Health
- Others

CT:VQ® enters U.S. Outpatient Market via SimonMed agreement

- Three-year commercial agreement
- One of the largest, fastest-growing and most influential physician-led outpatient radiology groups in the U.S.
- 170 site network across 10 states, 300+ radiologists
- SimonMed will also support the development of reimbursement evidence for CT:VQ®, sharing insurance and claims data

Philips and Veterans Affairs opportunity



Combined capabilities to build a compelling offer for 'owning the lung' and shared purpose



Veterans Affairs (VA) opportunity

- The U.S. PACT Act has appropriated US\$280 billion in additional funding over ten years for affected Veterans
- Requires screening for Deployment Related Respiratory Disease (DRRD) in over 4 Million eligible veterans
- Vanderbilt 'burn pit' publication demonstrates XV Technology® can detect the presence of constrictive bronchiolitis or DRCB
- Introduction of the AIR CARE for Veterans Act – this bill directs the VA to establish a pilot program to identify respiratory disorders using FDA approved software providing 'four-dimensional functional lung imaging'

Philips opportunity

- 4DMedical is well positioned to provide screening services – successful burn pits trial at Vanderbilt Medical Centre & research study with VA Houston
- 4DMedical and Philips Reseller Agreement – a commercial agreement to combine efforts to seek contract award(s) from the U.S. Office of Veterans Affairs, DoD and other non-government U.S. payers




Why does VA need to act?

- Surgical lung biopsy methodology (not scalable)
 - 3-day hospital stay
 - ~\$30k cost per procedure
 - 1 in 30 severe complication rate
 - 30k x 4m = \$120 Billion
- 4DMedical DRCB biomarker imaging
 - 30-minute outpatient scans
 - ~\$1,000 (CT \$650 and fluoroscopy \$350)
 - Non-invasive (98% accuracy correlation to biopsy)
 - 1k x 4m = \$4 Billion

CLEAR: expansion into acute pulmonary embolism market



- 4DMedical has launched CLEAR (Contrast-free Lung Evaluation for Acute Risk in pulmonary embolism)
- CLEAR's core study is a multi-centre, multinational, prospective, observational study comparing CT:VQ® head-to-head with CTPA in patients with suspected PE
- CLEAR creates a pathway for CT:VQ® to address the existing nuclear VQ market of approximately 1 million scans per year
- It also opens the materially larger, CTPA-dominated PE opportunity of approximately 5 million scans per year
- Together, these markets increase CT:VQ®'s obtainable market in the United States to US\$3 billion



Nuclear VQ

1 million scans per year
Solving supply side limitations to grow market to 1.5m scans
100% market capture
\$750m TAM @ 99% margins

CTPA

5 million scans per year
5x market of Nuclear VQ
Study underway
Readout in 2027
\$2.5B TAM

Clinical Validation



Major publication validates CT:VQ® for lung surgery

- Published in the American Journal of Respiratory and Critical Care Medicine, the world's leading respiratory medicine journal, and presented at the ATS 2026 International Conference, the world's largest pulmonary and respiratory medicine meeting.
- Study reports that integrating functional perfusion data with anatomical emphysema information from routine non-contrast CT imaging can enhance and streamline patient selection for lung volume reduction surgery (LVRS).
- This approach increased the proportion of patients responding to surgery from 46% to 76%.
- By identifying optimal candidates earlier using existing CT scans, CT:VQ® supports higher procedural success rates.

Major independent multicentre trial involving U.S. veterans validates the use of 4DMedical's imaging biomarkers

- Major multi-centre study published in Respiratory Research demonstrates that XV Technology® can reveal early and subtle forms of small airways disease often missed by standard tests such as spirometry and CT scans.
- Researchers from Vanderbilt University, Johns Hopkins, the University of Miami and Alfred Hospital in Melbourne showed that XV Technology® identifies disease-specific and severity-specific biomarker patterns in COPD and deployment-related constrictive bronchiolitis, even when conventional tests appear normal.
- These maps offer actionable insights to optimise patient care and may reduce the need for invasive biopsy.

A leading interventional pulmonologist presented work at AABIP showing that CT:VQ® reduced workup times for patients from 7 weeks to 3 weeks.

Commercial progress: Australia



TGA regulatory clearance for CT:VQ® and immediate deployments via key radiology clinics

- ✓ CT:VQ® cleared by the Therapeutic Goods Administration (TGA) and listed in the Australian Register of Therapeutic Goods (ARTG)
- ✓ Australia is uniquely positioned for rapid adoption:
 - ✓ >74 CT scanners per million people
 - ✓ ranks among the highest CT-utilisation markets globally
 - ✓ second-highest reported CT scanner density worldwide
- ✓ This extensive CT footprint enables CT:VQ® to become one of Australia's most accessible functional lung imaging modalities

Commercial agreements signed:

- Jones Radiology
- Qscan Radiology Clinics
- Perth Radiological Clinic
- Queensland Radiology Specialists
- Spectrum Medical Imaging
- Garran Medical Imaging
- Integral Diagnostics



4DMedical supports National Lung Cancer Screening Program

- ✓ Spectrum Medical Imaging expanded its multi-year agreement with 4DMedical including low-dose CT nodule detection for the National Lung Cancer Screening Program (NLCSP).
- ✓ The agreement broadens Spectrum's technology stack to include 4DMedical's product portfolio.

European expansion



Acquisition of contextflow

- ✓ Immediate European presence in one of the world's largest healthcare markets, with demand for advanced lung diagnostics supported by ageing populations, a high and rising burden of respiratory disease, and expanding lung cancer screening programs across the region
- ✓ Commencement of commercial operations, including the introduction of CT:VQ® into a new market
- ✓ Existing customer base and installed footprint across Europe, including established reimbursement workflows
- ✓ European-based team with deep regional expertise, established clinical relationships with leading institutions
- ✓ CE-marked product suite already deployed within the European MDR framework
- ✓ Significant post-acquisition European lung cancer screening deployment lead by Curagita, covering ~25,000 screening procedures across 25 German sites over three years, including Heidelberg University's Thoraxklinik




E.U. & U.K. regulatory clearances for CT:VQ® create a new, significant commercial opportunity

- ✓ CT is the dominant diagnostic imaging modality across European healthcare systems
- ✓ Large addressable market: 400,000+ VQ scans performed annually in the E.U.; 40,000 in the U.K.
- ✓ Instantly compatible with 13,000+ CT scanners combined in the E.U. & U.K.
- ✓ Combined population of ~520 million

Enhancing patient journey: key partnerships and investments



Lung Cancer screening: Find, Understand, Act



FY27 commercialisation priorities



- Commercial contracts with Philips VA sites
- Deployment-related respiratory disease screening, AIR CARE, PACT act
- Continued delivery of CT:VQ® across Academic Medical Centres and Health Systems
- Continued product adoption across community and radiology networks



- CT:VQ® penetration across existing contextflow sites
- Commercial engagement with key Academic Medical Centres and Health Systems
- Integration of contextflow into 4DMedical, realising commercial and cost synergies
- Expand commercial teams across the E.U. & U.K regions



- Continued CT:VQ® adoption across Radiology Networks and Public Hospital (AMC) system
- Referrer engagement programs across respiratory, cardiology and general practice
- Generate evidence supporting Medicare reimbursement with an item number
- Upsizing operations to support rapid global product rollout



- CLEAR study focusing on pulmonary embolism imaging – multiplying TAM by 6x
- Expand on Publications such as AJRCCM (Blue Journal) LVRS paper
- CT:VQ® health economic studies
- Continued regulatory approvals across new regions
- Penetration across global pharma market, device companies, AI marketplaces

Procedural matters

Formal Business

Items of Business



- Item 1: Financial Report, Directors' Report and Auditors Report
- Item 2: Remuneration Report
- Item 3: Re-election of Director, Dr Geraldine McGinty
- Item 4: Proposed issue of Equity Securities to Non-Executive Directors
- Item 5: Issue of RSUs and Options to the Managing Director and CEO
- Item 6: Issue of Options to the Executive Director and CFO
- Item 7: Renewal of approval for the Incentive Plan
- Item 8: Approval for proposed issue of contextflow Options
- Item 9: Ratification of prior issue of shares
- Item 10: Non-Executive Directors' Fees
- Item 11: Amendment to Constitution
- Item 12: Election of Director, Prof Christine Jenkins

Item 1: Financial Report, Directors' Report and Auditors Report

To receive and consider the Financial Report of the Company and its controlled entities and the Reports of the Directors and Auditor for the year ended 30 June 2026.

Item 2: Remuneration report

To consider, and if thought fit, to pass, the following as an ordinary resolution:

“That the Remuneration Report, as contained in the Directors’ Report for the year ended 30 June 2026, is adopted.”

In Favour	Against	Proxy Discretion	Abstain
26,282,333	75,081,299	3,758,435	3,713,215
25%	71.42%	3.58%	

Further Information:

- The Board unanimously recommends that Shareholders vote in favour of Item 2.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Item 3: Re-election of Dr Geraldine McGinty

To consider, and if thought fit, to pass, the following as an ordinary resolution:

“That, for the purposes of clause 13.3(b) of the Constitution, Listing Rule 14.4, and for all other purposes, Dr Geraldine McGinty, a non-executive Director appointed on 25 September 2023 and last re-elected on 2 November 2023, retires in accordance with clause 13.3(a) of the Constitution, and being eligible, is re-elected as a Director.”

In Favour	Against	Proxy Discretion	Abstain
169,049,756	3,493,904	3,872,206	1,134,961
95.82%	1.98%	2.19%	

Further Information:

- The Board (excluding Dr McGinty) unanimously recommends that Shareholders vote in favour of Item 3.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Items 4A to 4C: Proposed issue of Equity Securities to Directors

Item 4A

To consider, and if thought fit, to pass, the following as an ordinary resolution:
 “That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 11,406 Options to Mr John Livingston (or his nominee) under the Incentive Plan on the terms and conditions set out in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
88,492,141	13,487,545	4,042,949	2,812,647
83.47%	12.72%	3.81%	

Item 4B

To consider, and if thought fit, to pass, the following as an ordinary resolution:
 “That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 11,406 Restricted Stock Units to Dr Robert A. Figlin (or his nominee) under the Incentive Plan on the terms and conditions set out in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
89,217,748	12,858,869	3,905,544	2,853,121
84.18%	12.13%	3.69%	

Item 4C

To consider, and if thought fit, to pass, the following as an ordinary resolution:
 “That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 11,406 Restricted Stock Units to Dr Geraldine McGinty (or her nominee) under the Incentive Plan on the terms and conditions set out in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
89,126,384	12,925,869	4,034,544	2,748,485
84.01%	12.18%	3.80%	

Item 5: Issue of RSUs and Options to the Managing Director and CEO

To consider, and if thought fit, to pass, the following as an ordinary resolution:

“That, for the purposes of Listing Rule 10.14, sections 200B and 200E of the Corporations Act and for all other purposes, Shareholders approve the proposed issue of up to 1,697,041 RSUs and up to 945,724 Options, and potential termination benefits, to Managing Director and CEO, Dr Andreas Fouras, under the Incentive Plan and on the terms described in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
22,145,364	80,067,641	3,842,269	2,780,008
20.88%	75.50%	3.62%	

Further Information:

- The Board (other than Dr Fouras) unanimously recommends that Shareholders vote in favour of Item 5.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Item 6: Issue of Options to the Executive Director and CFO

To consider, and if thought fit, to pass, the following as an ordinary resolution:

“That, for the purposes of Listing Rule 10.14, sections 200B and 200E of the Corporations Act and for all other purposes, Shareholders approve the proposed issue of up to 4,909,708 Options, and potential termination benefits, to Executive Director and CFO, Mr Julian Sutton, under the Incentive Plan and on the terms described in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
18,091,787	84,018,086	3,834,014	2,891,395
17.08%	79.30%	3.62%	

Further Information:

- The Board (other than Mr Sutton) unanimously recommends that Shareholders vote in favour of Item 6.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Item 7: Renewal of approval for the Incentive Plan

To consider, and if thought fit, to pass, the following as an ordinary resolution:

“That, for the purposes of Listing Rules 7.1 and 7.2 Exception 13 and for all other purposes, the 4DMedical Long Term Incentive Plan (the key terms of which are summarised in the Explanatory Statement accompanying this Notice) and the future issues of securities under that plan, be approved, on the terms and conditions set out in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
34,189,520	67,783,176	3,849,851	2,802,929
32.31%	64.05%	3.64%	

Further Information:

- The Board does not make any recommendations in respect of this item 7 given their eligibility to participate in the Incentive Plan.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Item 8: Approval for the proposed issue of the contextflow Options

To consider, and if thought fit, to pass, the following as an ordinary resolution:

“That, for the purposes of Listing Rule 7.1 and for all other purposes, Shareholders approve the proposed issue of up to 3,766,252 Options on the terms and conditions set out in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
165,958,499	6,728,475	4,200,996	662,857
93.82%	3.80%	2.37%	

Further Information:

- The Board unanimously recommends that Shareholders vote in favour of Item 8.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Item 9: Ratification of prior issue of shares

To consider, and if thought fit, to pass, the following as an ordinary resolution:

“That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders ratify the prior issue of 34,907,388 Shares on the terms and conditions set out in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
94,820,694	1,524,033	4,016,312	590,001
94.48%	1.52%	4.00%	

Further Information:

- The Board unanimously recommends that Shareholders vote in favour of Item 9.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Item 10: Non-Executive Directors' Fee

To consider, and if thought fit, to pass, the following as an ordinary resolution:

“That for the purposes of clause 13.4 of the Company's constitution, ASX Listing Rule 10.17 and for all other purposes, the maximum aggregate director's fees that may be paid to the Directors of the Company as a whole (other than Executive Directors) for the financial year from and including the year commencing 1 July 2026, be increased by \$450,000 per annum from \$750,000 per annum to \$1,200,000 per annum on the terms and conditions set out in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
93,665,901	8,546,709	3,878,287	2,744,385
88.29%	8.06%	3.66%	

Further Information:

- The Board does not make any recommendations in respect of this item 10 as it involves payment of fees to Directors.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Item 11: Amendment to Constitution

To consider, and if thought fit, to pass, the following as a special resolution:

That, for the purposes of section 136(2) of the Corporations Act 2001 (Cth) and for all other purposes, the Members of the Company approve the amendments to the Company’s Constitution by inserting a new Clause 23.6(d) to increase the issue cap to 10% for the purposes of section 1100V of the Corporations Act, as set out in the Explanatory Statement.

In Favour	Against	Proxy Discretion	Abstain
94,376,894	76,712,948	4,642,834	1,818,151
53.70%	43.65%	2.64%	

Further Information:

- The Board unanimously recommends that Shareholders vote in favour of Item 11.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Item 12: Election of Director, Prof Christine Jenkins

To consider, and if thought fit, to pass, the following as an ordinary resolution:

“That, for the purposes of clause 13.1 of the Company's constitution, ASX Listing Rule 14.4, and for all other purposes, Prof Christine Jenkins, a non-executive director appointed on 23 September 2026, and being eligible, is re-elected as a director.”


In Favour	Against	Proxy Discretion	Abstain
159,693,565	4,573,892	2,537,792	341,720
95.74%	2.74%	1.52%	

Further Information:

- The Board (other than Prof Jenkins) unanimously recommends that Shareholders vote in favour of Item 12.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Poll

Q&A



4DMedical Limited (ASX:4DX)
Annual General Meeting
28 October 2026

Copyright © 4DMedical Limited 2026
Level 7, Melbourne Connect
700 Swanston Street
Melbourne, Victoria 3053
Australia

www.4dmedical.com

ABN 31 161 684 831